Whole-body MRI scans may not yield the kind of early detection rates their celebrity endorsers have led many to believe. 

Leqembi (lecanemab) was approved by the FDA in 2023. It is an infusion drug that has been shown to reduce Alzheimer’s-related cognitive decline by up to 27%. 

Mastering the art of effective prompts has become a coveted skill in the fast-growing field of AI. 

The study, which will be funded by a $2.3 million grant from the U.S. Department of Defense, will harness the power of advanced MRI technology to visualize the brain in a way that has not previously been possible.  

Chatbots may be able to accurately explain MRI results to patients in ways that radiologists are not routinely available to do. 

Gadoquatrane is now set to go through the regulatory review process on its trek to earning full FDA approval. 

New research refutes the notion that parts of the brain controlling specific extremities remap themselves following amputation, which would prevent patients from feeling pain associated with the removed appendage. 

Researchers say their findings suggest that medications that increase prefrontal dopamine "are an important lead to pursue.” 

A large study is shining a light on problematic racial disparities with respect to imaging utilization in men with suspected prostate cancer. 

DTI use could enable providers to make more informed decisions about athletes’ readiness to re-enter competition.